Bernadette Redd

706 total citations
24 papers, 366 citations indexed

About

Bernadette Redd is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Bernadette Redd has authored 24 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Bernadette Redd's work include Pancreatic and Hepatic Oncology Research (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Bernadette Redd is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Bernadette Redd collaborates with scholars based in United States, Italy and Japan. Bernadette Redd's co-authors include Catherine Brandon, Mohammadhadi Bagheri, Yuxing Tang, Zhiyong Lu, Youbao Tang, Ronald M. Summers, Ke Yan, Yifan Peng, Jing Xiao and Changqing Xie and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Bernadette Redd

20 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernadette Redd United States	8	163	133	98	54	53	24	366
Saba Shafi United States	10	135 0.8×	126 0.9×	50 0.5×	49 0.9×	26 0.5×	42	387
Hanlin Wang China	7	100 0.6×	85 0.6×	63 0.6×	31 0.6×	81 1.5×	12	372
Xinya Zhao China	8	79 0.5×	63 0.5×	58 0.6×	21 0.4×	30 0.6×	32	259
Ines P. Nearchou Japan	9	174 1.1×	84 0.6×	58 0.6×	32 0.6×	60 1.1×	12	263
Massimiliano Di Marzo Italy	10	131 0.8×	60 0.5×	65 0.7×	59 1.1×	60 1.1×	30	370
Huafeng Wang China	9	123 0.8×	66 0.5×	57 0.6×	21 0.4×	75 1.4×	25	311
Ling Huo China	8	59 0.4×	77 0.6×	57 0.6×	34 0.6×	69 1.3×	19	335
F Ng Singapore	8	232 1.4×	144 1.1×	87 0.9×	79 1.5×	18 0.3×	8	494
Qiufeng Zhao China	7	50 0.3×	138 1.0×	51 0.5×	19 0.4×	33 0.6×	22	301
Jiamei Chen China	13	107 0.7×	66 0.5×	88 0.9×	41 0.8×	61 1.2×	25	350

Countries citing papers authored by Bernadette Redd

Since Specialization

Citations

This map shows the geographic impact of Bernadette Redd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernadette Redd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernadette Redd more than expected).

Fields of papers citing papers by Bernadette Redd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernadette Redd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernadette Redd. The network helps show where Bernadette Redd may publish in the future.

Co-authorship network of co-authors of Bernadette Redd

This figure shows the co-authorship network connecting the top 25 collaborators of Bernadette Redd. A scholar is included among the top collaborators of Bernadette Redd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernadette Redd. Bernadette Redd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Panebianco, Valeria, Alberto Briganti, Jason A. Efstathiou, et al.. (2025). Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee. European Urology.

Simon, Nicholas I., Daniel M. Girardi, Lisa Ley, et al.. (2025). A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale. Future Oncology. 21(10). 1171–1177.

Ma, Chi, Changqing Xie, Meng Liu, et al.. (2025). Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers. Cancer Letters. 632. 217975–217975. 1 indexed citations

Woo, Sungmin, Lyndon Luk, Valdair Francisco Muglia, et al.. (2025). VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee. European Radiology. 36(2). 1093–1104. 1 indexed citations

Simon, Nicholas I., Daniel M. Girardi, Lisa Ley, et al.. (2025). E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale. Future Oncology. 21(13). 1625–1630. 1 indexed citations

Monge, Cecilia, Changqing Xie, Yuta Myojin, et al.. (2024). Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma. Cancer Medicine. 13(3). e6912–e6912. 6 indexed citations

Fuss, Ivan J., Jenna Bergerson, Jacqueline Laurin, et al.. (2024). Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study. Alimentary Pharmacology & Therapeutics. 59(12). 1527–1538. 2 indexed citations

Giudice, Elena, Tzu‐Ting Huang, Jayakumar R. Nair, et al.. (2024). The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nature Communications. 15(1). 2805–2805. 16 indexed citations

Myojin, Yuta, Cecilia Monge, Changqing Xie, et al.. (2024). VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial. Journal for ImmunoTherapy of Cancer. 12(1). e008079–e008079. 7 indexed citations

10.

Turriff, Amy, Christina M. Annunziata, Ashkan A. Malayeri, et al.. (2024). Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer. New England Journal of Medicine. 391(22). 2123–2132. 7 indexed citations

11.

Simon, Nicholas I., Lisa M. Cordes, Elizabeth Smith, et al.. (2024). SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS4627–TPS4627. 3 indexed citations

12.

Hsu, Li‐Yueh, et al.. (2023). Comparison of CT and Dixon MR Abdominal Adipose Tissue Quantification Using a Unified Computer-Assisted Software Framework. Tomography. 9(3). 1041–1051. 7 indexed citations

13.

Monge, Cecilia, Changqing Xie, Yuta Myojin, et al.. (2023). Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 11(2). e005640–e005640. 46 indexed citations

14.

Gamble, Lauren A., et al.. (2023). Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics. npj Breast Cancer. 9(1). 77–77. 4 indexed citations

15.

Xie, Changqing, Bernadette Redd, Bradford J. Wood, et al.. (2023). A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 41(4_suppl). TPS624–TPS624. 11 indexed citations

16.

Monge, Cecilia, Erica C. Pehrsson, Changqing Xie, et al.. (2022). A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. The Oncologist. 27(3). e273–e285. 32 indexed citations

17.

Xie, Changqing, Austin G. Duffy, Gagandeep Brar, et al.. (2020). Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 26(10). 2318–2326. 65 indexed citations

18.

Tang, Yuxing, Youbao Tang, Yifan Peng, et al.. (2020). Automated abnormality classification of chest radiographs using deep convolutional neural networks. npj Digital Medicine. 3(1). 70–70. 146 indexed citations

19.

Gafni, Rachel I., et al.. (2020). SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

20.

Monge, Cecilia, Changqing Xie, Gagandeep Brar, et al.. (2020). A phase I/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer. European Journal of Cancer. 138. S57–S58. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact